Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients

The current World Health Organization (WHO) 2021 classification of human glioma is based on key molecular biomarkers to define neoplastic entities. This review further delineates mutant IDH (isocitrate dehydrogenase) from wild-type IDH disease, a necessity given the large survival gap between mutant...

Full description

Saved in:
Bibliographic Details
Published in:International journal of general medicine 2023-01, Vol.16, p.393-403
Main Authors: Priambada, Dody, Thohar Arifin, Muhamad, Saputro, Abdi, Muzakka, Azka, Karlowee, Vega, Sadhana, Udadi, Bakhtiar, Yuriz, Prihastomo, Krisna Tsaniadi, Risdianto, Ajid, Brotoarianto, Happy Kurnia, Andar, Erie, Muttaqin, Zainal
Format: Article
Language:English
Subjects:
Biomarkers
Brain cancer
Brain damage
Brain research
Consent
DNA damage
Enzymes
Genomes
Glioma
idh1
immunohistochemical expression
indonesia
Labeling
Medical prognosis
Metastasis
Mutation
Nervous system
Original Research
prognosis
Proteins
Radiation
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current World Health Organization (WHO) 2021 classification of human glioma is based on key molecular biomarkers to define neoplastic entities. This review further delineates mutant IDH (isocitrate dehydrogenase) from wild-type IDH disease, a necessity given the large survival gap between mutant IDH and wild-type IDH tumors. In Indonesia, there are currently few reports on the distribution and significance of these mutations. Therefore, this research aims to determine the relationship between IDH mutations, as well as clinicopathological and prognostic factors in patients with gliomas. Other immunohistochemical markers including ATRX (alpha-thalassemia/mental retardation, X-linked), Ki67 and GFAP (glial fibrillary acidic protein) expression were also evaluated. Forty-two glioma samples were collected from patients who underwent surgery at Dr. Kariadi General Hospital in Semarang, Central Java, Indonesia. Fresh and paraffin-embedded, formalin-fixed tissue samples were removed and sectioned for hematoxylin and eosin staining, immunohistochemistry, and IDH analysis of mutation. Medical records were used to collect clinicopathological and survival data. IDH1 mutations were discovered in 32 (76,1%) patients, and those with IDH1 mutation had longer overall survival when corresponded to patients with IDH1-wild-type. Lower expression of Ki67 was discovered to be very associated with a better prognosis. IDH1 mutations status showed a significant relationship with prognosis in patients with glioma. Meanwhile, other markers (ATRX, Ki67, and GFAP) did not correlate with the prognosis.
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S397550